Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | ACP1 | P24666 | 2/20 | 0.33 |
| ▸ | CDC25B | P30305 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964968 | 0.87 | BACE1 (0.39) | BACE1GLANPSR1HSD17B10ALDH1A1 | |
| SCHEMBL7995598 | 0.86 | HSD17B10 (0.52) | BACE1GLANPSR1HSD17B10PTPN1 | |
| SCHEMBL20351497 | 0.83 | BACE1 (0.41) | BACE1GLANPSR1ALDH1A1KDM4E | |
| SCHEMBL28927137 | 0.83 | LMNA (0.54) | BACE1GLANPSR1HSD17B10PTPN1 | |
| SCHEMBL20826897 | 0.82 | KDM4E (0.50) | BACE1GLANPSR1HSD17B10PTPN1 | |
| SCHEMBL587175 | 0.82 | ALDH1A1 (0.46) | BACE1GLANPSR1ALDH1A1KDM4E | |
| SCHEMBL7243740 | 0.81 | PTPN1 (0.49) | BACE1HSD17B10PTPN1ALDH1A1ACP1 | |
| SCHEMBL3821085 | 0.80 | BACE1 (0.40) | BACE1GLANPSR1ALDH1A1KDM4E | |
| SCHEMBL29663487 | 0.80 | BACE1 (0.40) | BACE1GLANPSR1HSD17B10PTPN1 | |
| SCHEMBL2995240 | 0.80 | SLC25A5 (0.46) | BACE1GLANPSR1PTPN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-62042975-A | — | — | None | — | — | JP | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VECTIVBIO COMET AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-04-06 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VECTIVBIO COMET AG, F/K/A COMET THERAPEUTICS, INC. (CH) | 2023-03-09 | — | — | US | disclosed |
| CN-113727966-A | Panthenol derivatives and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| CN-113727986-A | Cyclic panthenol derivative and use thereof | 彗星医疗股份有限公司 | 2021-11-30 | — | — | CN | disclosed |
| EP-3887381-A2 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | Comet Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-5874589-A | Methods for synthesizing diverse collections of tetramic acids and derivatives thereof | GLAXO WELLCOME, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| US-5767131-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA, INHIBITION OF CHOLESTEROL SYNTHESIS, LOWERING OF INTRAOCULAR PRESSURE; ALPHA-ADRENERGIC RECEPTOR DISEASES | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
| WO-1994022829-A2 | DIHYDROPYRIDINES AND NEW USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5232898-A | Herbicides | CIBA-GEIGY CORPORATION (US) | 1993-08-03 | — | — | US | disclosed |
| EP-0434778-A1 | HETEROCYCLIC COMPOUNDS | CIBA-GEIGY AG (CH) | 1991-07-03 | — | — | EP | disclosed |
| WO-1990015057-A1 | HETEROCYCLIC COMPOUNDS | CIBA-GEIGY AG (CH) | 1990-12-13 | — | — | WO | disclosed |
| JP-S6242975-A | PRODUCTION OF HETEROCYCLIC COMPOUND | NIPPON SODA CO LTD | 1987-02-24 | — | — | JP | disclosed |
| EP-0054970-B1 | DERIVATIVES OF 7-BETA-(KETOXIMINOACYLAMIDO)-CEPH-3-EM-4-CARBOXYLIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | I. S. F. Società per Azioni (IT) | 1985-07-17 | — | — | EP | disclosed |
| US-4465831-A | ANTIBIOTICS, BACTERICIDES | ISF S.P.A. (IT) | 1984-08-14 | — | — | US | disclosed |
| EP-0054970-A2 | Derivatives of 7-beta-(ketoximinoacylamido)-ceph-3-em-4-carboxylic acids, process for their preparation and their pharmaceutical compositions containing them | I. S. F. Società per Azioni (IT) | 1982-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107216-A1 | PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, NQO1, VKORC1 | BACE1 4499/4885GLA 760/4885NPSR1 2430/4885 |
| US-20230072313-A1 | CYCLIC PANTETHEINE DERIVATIVES AND USES THEREOF | VNN1, VKORC1, PANK3 | BACE1 4463/4885GLA 900/4885NPSR1 2808/4885 |
| US-12037354-B2 | Cyclic pantetheine derivatives and uses thereof | VNN1, VKORC1, PANK3 | BACE1 4463/4885GLA 900/4885NPSR1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.